Hexpol TPE has announced a 57 Million SEK investment at their company in Åmål, Sweden, to support increasing demand and evolving market requirements. The investment will expand production capacity and ensure product safety standards across their materials portfolio. A new production hall is being constructed, dedicated to medical production, with strict cleanliness, traceability, and reproducibility controls. It has been designed to minimise contamination risks and will house a new twin-screw compounding line with gravimetric feeders and advanced monitoring systems adopted for medical production. Construction of the new production hall began in September 2021. The aim is to complete the project by autumn 2022.
Ralph Wolkener, President Hexpol Compounding, Europe/Asia, commented, „We’re investing in capability and capacity. Ensuring we maintain the very high standards, processes, and operations required for our customers while expanding our production capacity.
Carsten Rüter, President of Hexpol Compounding Global Purchasing/Technology, added, „This project also lays the foundation for future development with optimised internal logistics and increased automation and robotics.“
Georg Brunstam, President and CEO Hexpol Group, added, „This investment confirms Hexpol’s ongoing commitment to this important product area. For the team in Åmål, it’s part of their continuing story and development. Hexpol invest to ensure we deliver the know-how, performance and reliability our customers deserve.“
The company specialises in TPE materials for sensitive and regulated applications such as medical devices, toys, consumer, automotive and food contact. Sustainability and biobased materials are also driving their strategy. Hexpol TPE produced their first medical compounds in the 1990s and launched the Mediprene range in 2004. Continuous investment in technology, people and processes contributed to the company becoming the first TPE compounder in Europe to gain the ISO 13485 accreditation in 2007.